



UNIVERSITY OF LEEDS

This is a repository copy of *Prognostic Significance of Incidental Nonsustained Ventricular Tachycardia Detected on Pacemaker Interrogation*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/140470/>

Version: Accepted Version

Article:

Jamil, HA, Mohammed, SA, Gierula, J orcid.org/0000-0001-9588-191X et al. (5 more authors) (2019) Prognostic Significance of Incidental Nonsustained Ventricular Tachycardia Detected on Pacemaker Interrogation. *American Journal of Cardiology*, 123 (3). pp. 409-413. ISSN 0002-9149

<https://doi.org/10.1016/j.amjcard.2018.10.040>

(c) 2018, Elsevier Ltd. This manuscript version is made available under the CC BY-NC-ND 4.0 license <https://creativecommons.org/licenses/by-nc-nd/4.0/>

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Title: Prognostic Significance of Incidental Non-Sustained Ventricular Tachycardia Detected on Pacemaker Interrogation

Haqeel A Jamil PhD^{1†}, Sajeel A Mohammed MD^{1†}, John Gierula PhD¹, Maria F Paton MSc¹,
Judith E Lowry MSc¹, Richard M Cubbon PhD¹, Mark T Kearney MD¹, Klaus KA Witte MD¹

¹ Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK

[†] Joint first authors

Declarations of interest: none

* Corresponding author:

Dr Haqeel Jamil (c/o Dr K. Witte)

Leeds Institute of Cardiovascular and Metabolic Medicine

LIGHT building, University of Leeds

Clarendon Way, Leeds, UK, LS2 9JT

Phone: (+44) 113 3926108

E-mail: haqeel@doctors.org.uk

Word count: 2,202

Short title : Clinical significance of incidental non-sustained ventricular tachycardia on pacemaker interrogation

ABSTRACT

Symptomatic sustained ventricular tachycardia is a life threatening arrhythmia requiring prompt treatment. However, the risk associated with asymptomatic non-sustained ventricular tachycardia (NSVT) detected on routine permanent pacemaker (PPM) interrogation in patients with known cardiac conduction disease is unknown. Our aim is to determine if asymptomatic NSVT detected on PPM interrogation is associated with increased mortality. As part of a prospective observational cohort study, 582 patients with long-term pacemakers were recruited at a tertiary cardiac centre, and followed for 4 ± 1.96 years (mean \pm SD). At each subsequent pacemaker check, any symptoms and ventricular high-rate episodes (VHR) were recorded. We excluded 17 patients due to incomplete data. In, the remaining 565 patients (57% male, age 74.5 ± 19.2 years, left ventricular ejection fraction (LVEF) 50.0 ± 11.3 %), NSVT was found in 125 (22.1%) patients with a higher prevalence in males (65% v 54%; $p=0.033$). Those with NSVT were more likely to have had coronary artery disease ($p=0.000$) or previous myocardial infarction ($p=0.015$). After correction for baseline variables, NSVT had no impact on survival (($n=52$ (42%) v $n=162$ (37%); log rank $p= 0.331$, hazard ratio (HR): 0.927, 95% CI: 0.678 to 1.268, $p=0.697$). In conclusion, asymptomatic NSVT identified on PPM interrogation does not appear to be associated with increased mortality, thus whether treatment to suppress this arrhythmia is of benefit remains unproven.

Keywords: Pacemaker, asymptomatic, non-sustained, ventricular tachycardia, LV systolic dysfunction

INTRODUCTION

Asymptomatic non-sustained ventricular tachycardia (NSVT) is a short-lived arrhythmia that is often found in both healthy individuals and those with heart disease.[1] The identification of asymptomatic NSVT creates a clinical dilemma since its prognostic significance and therefore the benefit of treatment is unclear.[2] This quandary is especially frequent in patients with confirmed cardiac conduction disorders and implanted permanent pacemakers (PPMs), which can also function as cardiac monitors capable of identifying atrial and ventricular high rate (VHR) episodes during routine pacemaker interrogation.[3] The approach to managing asymptomatic pacemaker-identified VHR episodes remains limited by lack of evidence on the prognostic significance of NSVT and the effects of suppression.[4,5] We therefore set out to establish the associations and prognostic relevance of NSVT detected during routine pacemaker follow-up.

METHODS

Between January 2008 and December 2012, we invited all adult patients (n=730, figure 1) listed for pulse generator replacement (PGR) at a tertiary cardiac referral centre (Leeds General Infirmary) to attend for an assessment and enrolment into a prospective observational cohort study. Patients with resynchronisation and/or defibrillator devices were excluded. At a single study visit we recorded demographic and clinical details, including the presence of pre-defined co-variables, from 582 participants, interrogated the pacemaker and performed an echocardiogram. We defined mild, moderate and severe left ventricular systolic dysfunction (LVSD) as an LV ejection fraction (LVEF) of $\leq 55\%$, $\leq 45\%$ and $\leq 35\%$ respectively.

Subsequent patient follow-up occurred in line with usual care including documentation of any VHR episodes, and any clinician-mediated management thereof. After the censor point, these episodes were examined by two investigators (JG and SM), blinded to the outcome of the patient, and confirmed to be NSVT based upon the most commonly used definition of three or more consecutive beats of ventricular origin, with an RR interval of less than 600 ms (>100 beats/min) and lasting less than 30 seconds.[6] Both single (VVI) and dual chamber devices were included. In VVI devices, ventricular tachycardia was defined by speed of onset and rhythm regularity, while v-a dissociation was also used in dual chamber device analysis. We also recorded the duration of the longest episode and the total number of episodes.

The primary end-point was all-cause mortality, with the censor date set to 1stSeptember 2015.

Data were analysed within SPSS version 22 for Windows (SPSS, Armonk, New York). Normality of continuous variables was assessed using the Shapiro-Wilk test. Normally distributed continuous variables are described as mean \pm standard deviation while non-normally distributed variables are described as median and interquartile range.

Patients were grouped into those with and without NSVT. Normally distributed continuous variables were compared between these groups using 2-sample t-tests. Where assumptions for the chi-squared test were met, the chi-squared test was used for categorical variables. In exploring NSVT 'dose' effect we categorised patients into

clusters of those with no NSVT, those with 1-10 episodes, and those with >10 episodes. Continuous variables of relevance were compared across these categories using ANOVA.

Multiple regression analysis was used to predict the importance of co-variables in terms of their relationship with other co-variables and the presence of NSVT. In the subgroup of NSVT patients who received a change to treatment, we used a paired t-test to assess changes in frequency of NSVT.

Cox proportional hazard analysis was used to determine co-variables related to outcomes and their relative importance. Survival (measured in number of days survived from first date of NSVT diagnosis to death or censor date) was depicted using Kaplan Meier survival graphs, and compared using the log-rank test. For all analyses we accepted a p-value less than 0.05 as significant. The study was approved by the Leeds West Research Ethics Committee (08/H1307/12).

A recent large study exploring the prognostic value of NSVT was able to demonstrate significance using a cohort of 325 participants, of which 90 had evidence of NSVT.[7] Furthermore, several previous pacemaker studies had shown that the prevalence of detected NSVT ranges from 20-25%.[3,7,11,12] Thus our aim was to recruit a minimum of 500 participants, with an estimated minimum NSVT cohort of 100.

RESULTS

The original cohort included 582 patients of whom we excluded 17 patients due to loss to follow-up (n=7), devices incapable of detecting NSVT (n=5) and incomplete NSVT data due to having a device upgrade to ICD/CRT during the follow up period (n=5). We therefore had a complete dataset on 565 patients (Table 1). Those excluded as a group, were not different in terms of age, medication use and important clinical variables.

Patients in the final cohort (56.5% male, 74.5 ± 19.2 years, left ventricular ejection fraction 50.0 ± 11.3) had their pacemaker for 9.8 ± 5.1 years, with mean RV pacing percentage of $72.3\% \pm 7.1$.

During the follow-up period of 4 ± 1.96 years (mean \pm SD), NSVT was confirmed in 125 (22.1%) of the population (Table 1). The prevalence of NSVT was greater in men than women (n=81, 64.8%; p=0.033) and in patients with coronary artery disease (CAD; p=0.000) or previous myocardial infarction (MI; p=0.015).

There was no significant difference between those with and without NSVT in terms of age or other co-morbidities, including hypertension, atrial fibrillation, diabetes, renal function or medication use. There was no difference in presence of NSVT in those with mild (LVEF $\leq 55\%$; n=23 (20%); p=0.341), moderate (LVEF $\leq 45\%$; n=21 (24%); p=0.280) or severe (LVEF $\leq 35\%$; n=7 (20%); p=0.624) LVSD. The median NSVT duration was 11 beats (interquartile range: 8 beats), and the median number of episodes was 2 (interquartile range: 5).

We had vital status for 99% of enrolled patients (558 of the 565 in the cohort). Mean total follow-up time (4.0+/-1.9 years) was the same in the two groups. Mortality at the censor point was not different between those with and without NSVT (n=52 (42%) v n=162 (37%); log rank p= 0.331, hazard ratio (HR) for mortality: 0.927, 95% CI: 0.678 to 1.268, p=0.697, figure 2). There were also no survival differences between those with and without NSVT in the subgroup with coronary artery disease (20/49 (40.9%) v 34/84 (40.5%); log rank p=0.969, HR for mortality: 1.03, 95% CI: 0.592 to 1.791, p=0.917), with moderate-severe LVSD (LVEF \leq 45%; 12/28 (42.8%) v 48/94 (51.1%); log rank p=0.362, HR for mortality: 1.25, 95% CI: 0.664 to 2.362, p=0.478) or severe LVSD (LVEF \leq 35%; HR for mortality: 0.817, 95% CI 0.404 to 1.65, p=0.33) .

We assigned patients with NSVT into 3 quantitative ordinal categories according to the total number of episodes recorded (Table 2). Survival analyses based upon the number of episodes recorded did not reveal any significant differences between these three groups (Log rank p=0.898).

DISCUSSION

The present project explores an important therapeutic dilemma frequently encountered during routine pacemaker follow-up. Our results are from a representative, prospectively collected and contemporary cohort of pacemaker patients, and are in keeping with recently reported studies by Allen SM et al and Gabriels J et al, showing NSVT to be a benign finding.[7, 8] Our data did not show a relationship between the presence of NSVT and significant LVSD, however the

numbers of patients in the sub-groups were likely too small to reach statistical significance.

NSVT has poor symptom-rhythm correlation, even in patients with heart failure,[9,10] and may be discovered during ambulatory monitoring or on interrogation of implanted cardiac devices. Whilst the prevalence of asymptomatic NSVT found on short-term Holter monitors is thought to be around 4-5%,[4,11] the prevalence in our dataset is similar to that found in other studies of pacemaker patients at around 20-25%.[3,13,12,13]

The prognostic relevance of asymptomatic NSVT is unclear.[3,5,14] Even in patients with overt cardiovascular disease, including left ventricular systolic dysfunction, there are conflicting reports of whether NSVT is associated with increased mortality.[15,16,17,18,19] This lack of clarity extends to people with pacemakers. The two other prospective studies to examine the epidemiology of NSVT in people with pacemakers either did not report on outcomes,[13] or excluded patients with LVSD,[12] making ours the only investigation to date to present the lack of prognostic relevance of NSVT presence/duration within a general pacemaker population.

The mortality rate seen in our cohort was higher than that observed in other similar studies, such as the work of Fleg et al, which looked at 98 healthy subjects aged over 60 years, who were deemed 'free of cardiac disease'. [13] However, our data represent a larger and older cohort with multiple cardiovascular co-morbidities, thus a higher mortality rate would be expected.

The association with CAD or IHD is likely a consequence of the structural pathophysiological changes that occur within the myocardium in response to cardiac ischaemia, which can lead to fibrosis, scarring and disruption of cardiac electrical conduction pathways.[5,16] However, we have demonstrated that in our patients NSVT does not appear to predict higher all-cause mortality, even in the context of CAD.[7]

Based upon the finding that asymptomatic NSVT is not a convincing marker of prognosis in patients with pacemakers, adding treatments to suppress this rhythm disturbance remains unproven, and may inadvertently lead to iatrogenic sequelae. Previous studies have also indicated that treatment aimed at suppression of NSVT may not be associated with improved outcomes.[20,21]

Furthermore, the most recent European guidelines suggest that NSVT is rarely of any haemodynamic significance and treatment should only be considered in those individuals who are either symptomatic or have a very high NSVT burden (>24%) that may be contributing to LVSD.[4] In such cases, beta-blockers, amiodarone or radiofrequency catheter ablation may be considered.

Although our baseline patient data were collected prospectively, the NSVT data were verified retrospectively at the censor point exposing our analysis to the biases inherent in observational data including unknown confounders of the relationship between NSVT and other variables and outcome.

The analysis was also limited to all-cause mortality due to insufficient data to allow differentiation between types or causes of mortality, or other relevant end-points, such as hospitalisation.

Our results demonstrate that NSVT in an unselected large cohort of pacemaker patients is not a predictor of adverse outcome, even in the higher risk subgroups and that treatment of asymptomatic episodes may not be beneficial. Our data should serve to reassure physicians managing patients with pacemakers, the patients themselves and their carers of the benign nature of asymptomatic NSVT identified during pacemaker interrogation, irrespective of other co-morbidities.

Acknowledgements/Funding

KKW holds an NIHR Clinician Scientist Award

JG holds an NIHR-HCS Fellowship Award

MFP holds an NIHR ICA Fellowship Award

JEL is funded by a Leeds Charitable Foundation Fellowship

RMC holds an Intermediate Fellowship from the British Heart Foundation

MTK is a British Heart Foundation Professor of Cardiology

JG and KKW hold unrestricted research grants from Medtronic Europe

The authors acknowledge the consistent administrative support provided by Mrs Andrea Marchant.

This research took place in the National Institute for Health Research Leeds Cardiovascular Clinical Research Facility at Leeds Teaching Hospitals NHS Trust.

References

1. Katritsis DG, Zareba W, Camm AJ. Nonsustained ventricular tachycardia. *J Am Coll Cardiol* 2012;60:1993–2004.
2. Mitra RL, Buxton AE. The clinical significance of nonsustained ventricular tachycardia. *J Cardiovasc Electrophysiol* 1993;4:490–496.
3. Crossley GH, Chen J, Choucair W, Cohen TJ, Gohn DC, Johnson WB, Kennedy EE, Mongeon LR, Serwer GA, Qiao H, Wilkoff BL and PREFER Study Investigators. Clinical benefits of remote versus transtelephonic monitoring of implanted pacemakers. *J Am Coll Cardiol* 2009;54:2012–2019.

4. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekvål TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). *Eur Heart J* 2015;36:2793-2867.
5. Engstrom G, Hedblad B, Janzon L, Juul-Moller S. Ventricular arrhythmias during 24-h ambulatory ECG recording: incidence, risk factors and prognosis in men with and without a history of cardiovascular disease. *J Intern Med* 1999;246:363–372.
6. American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology), Buxton AE, Calkins H, Callans DJ, DiMarco JP, Fisher JD, Greene HL, Haines DE, Hayes DL, Heidenreich PA, Miller JM, Poppas A, Prystowsky EN, Schoenfeld MH, Zimetbaum PJ, Goff DC, Grover FL, Malenka DJ, Peterson ED, Radford MJ, Redberg RF. ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop D. *J Am Coll Cardiol* 2006;48:2360–2396.

7. Allen MS, Abrich VA, Bibby PS, Fishman D, Shen W, Sorajja D. Prevalence and Prognostic Significance of Nonsustained Ventricular Tachycardia in Patients With a Left Ventricular Ejection Fraction from 35% to 50%. *Am J Cardiol* 2018;121:330–335.
8. Gabriels J, Wu M, Rosen L, Patel A, Goldner B. Clinical Significance of Nonsustained Ventricular Tachycardia on Stored Electrograms in Permanent Pacemaker Patients. *Pacing Clin Electrophysiol* 2016 Dec;39(12):1335-1339.
9. Senges JC, Becker R, Schreiner KD, Bauer A, Weretka S, Siegler K, Kuebler W, Schoels W. Variability of Holter electrocardiographic findings in patients fulfilling the noninvasive MADIT criteria. Multicenter Automatic Defibrillator Implantation Trial. *Pacing Clin Electrophysiol* 2002;25:183–190.
10. Callans DJ. Evaluation and Treatment of Arrhythmias in Heart Failure. In: Jessup ML, Loh E (eds) Heart Failure. *Contemporary Cardiology*. Humana Press, Totowa, NJ; 2003. 253-269.
11. Marine JE, Shetty V, Chow G V, Wright JG, Gerstenblith G, Najjar SS, Lakatta EG, Fleg JL. Prevalence and prognostic significance of exercise-induced nonsustained ventricular tachycardia in asymptomatic volunteers: BLSA (Baltimore Longitudinal Study of Aging). *J Am Coll Cardiol* 2013;62:595–600.
12. Seth N, Kaplan R, Bustamante E, Kulkarni C, Subacius H, Rosenthal JE, Passman R. Clinical significance of nonsustained ventricular tachycardia on routine monitoring of pacemaker patients. *Pacing Clin Electrophysiol* 2015;38:980–988.
13. Faber TS, Gradinger R, Treusch S, Morkel C, Brachmann J, Bode C, Zehender M; EVENTS Investigators. Incidence of ventricular tachyarrhythmias during permanent

pacemaker therapy in low-risk patients results from the German multicentre EVENTS study. *Eur Heart J* 2007;28:2238–2242.

14. Fleg JL, Kennedy HL. Long-term prognostic significance of ambulatory electrocardiographic findings in apparently healthy subjects ≥ 60 years of age. *Am J Cardiol* 1992;70:748–51.
15. Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2005;45:697–704.
16. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. *J Am Coll Cardiol* 2003;42:873–879.
17. Santini M, Russo M, Botto G, Lunati M, Proclemer A, Schmidt B, Erdogan A, Helmling E, Rauhe W, Desaga M, Santi E, Messier M, Boriani G. Clinical and arrhythmic outcomes after implantation of a defibrillator for primary prevention of sudden death in patients with post-myocardial infarction cardiomyopathy: The Survey to Evaluate Arrhythmia Rate in High-risk MI patients (SEARCH-MI). *Europace* 2009;11:476-482.
18. Holmes J, Kubo SH, Cody RJ, Kligfield P. Arrhythmias in ischemic and nonischemic dilated cardiomyopathy: prediction of mortality by ambulatory electrocardiography. *Am J Cardiol* 1985; 55:146–151.

19. Pelliccia F, Gallo P, Cianfrocca C, d'Amati G, Bernucci P, Reale A. Relation of complex ventricular arrhythmias to presenting features and prognosis in dilated cardiomyopathy. *Int J Cardiol* 1990;29:47–54.
20. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. The preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. *N Engl J Med* 1989;321:406–412.
21. Friedman LM, Byington RP, Capone RJ, Furberg CD, Goldstein S, Lichstein E. Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia. *J Am Coll Cardiol* 1986;7:1–8.

Number of figures: 2

Figure 1: Study recruitment follow chart

Figure 2: Kaplan meier survival analysis curve: no significant difference in survival of patients with NSVT compared to those with no NSVT (log rank analysis p value = 0.697).

Number of tables: 2

Table 1: Baseline patient demographic characteristics (n=565)

Table 2: NSVT episode categories and corresponding characteristics (n=125)